Jan Hasselström

Jan Hasselström

Auto-generated profile, based on publicly available information

Jan Hasselström

Department of Neurobiology, Care Sciences and Society, Section of Family Medicine and Primary Care, Karolinska Institutet

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2011 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
LGLars L. Gustafsson
Lars L. Gustafsson
BWBjörn Wettermark
Björn Wettermark
BGBrian Godman
Brian Godman
EAEva Andersén‐Karlsson
Eva Andersén‐Karlsson
UBUlf Bergman
Ulf Bergman
FCfor the Regional Drug Expert Consortium
for the Regional Drug Expert Consortium
Abstract:  The aim was to present and evaluate the impact of a comprehensive strategy over 10 years to select, communicate and achieve adherence to essential drug recommendations (EDR) in ambulatory care in a metropolitan healthcare region. EDRs were issued and launched as a ‘Wise List’ by the regional Drug and Therapeutics Committee in Stockholm. This study presents the concept by: (i) documenting the process for selecting, communicating and monitoring the impact of the ‘Wise List’; (ii) analysing the variation in the number of drug substances recommended between 2000 and 2010; (iii) assessing the attitudes to the ‘Wise List’ among prescribers and the public; (iv) evaluating the adherence to recommendations between 2003 and 2009. The ‘Wise List’ consistently contained 200 drug substances for treating common diseases. The drugs were selected based on their efficacy, safety, suitability and cost‐effectiveness. The ‘Wise List’ was known among one‐third of a surveyed sample of the public in 2002 after initial marketing campaigns. All surveyed prescribers knew about the concept and 81% found the recommendations trustworthy in 2005. Adherence to recommendations increased from 69% in 1999 to 77% in 2009. In primary care, adherence increased from 83% to 87% from 2003 to 2009. The coefficient of variation (CV%) decreased from 6.1% to 3.8% for 156 healthcare centres between these years. The acceptance of the ‘Wise List’ in terms of trust among physicians and among the public and increased adherence may be explained by clear criteria for drug recommendations, a comprehensive communication strategy, electronic access to recommendations, continuous medical education and involvement of professional networks and patients.

1 October 2002 in European journal of pain
Verified
Journal Article
Closed access
JHJan Hasselström
Jan Hasselström
JLJenny Liu‐Palmgren
Jenny Liu‐Palmgren
GRGörel Rasjö‐Wrååk
Görel Rasjö‐Wrååk

15 October 2014 in Scandinavian Journal of Primary Health Care
Verified
Journal Article
Open access
CLCecilia Lenander
Cecilia Lenander
BEBirgitta Elfsson
Birgitta Elfsson
BDBirgitta Danielsson
Birgitta Danielsson
PMPatrik Midlöv
Patrik Midlöv
JHJan Hasselström
Jan Hasselström
To determine whether a pharmacist-led medications review in primary care reduces the number of drugs and the number of drug-related problems. Prospective randomized controlled trial. Liljeholmen Primary Care Centre, Stockholm, Sweden. 209 patients aged ≥ 65 years with five or more different medications. Intervention. Patients answered a questionnaire regarding medications. The pharmacist reviewed all medications (prescription, non-prescription, and herbal) regarding recommendations and renal impairment, giving advice to patients and GPs. Each patient met the pharmacist before seeing their GP. Control patients received their usual care. Drug-related problems and number of drugs. Secondary outcomes included health care utilization and self-rated health during 12 months of follow-up. No significant difference was seen when comparing change in drug-related problems between the groups. However, a significant decrease in drug-related problems was observed in the intervention group (from 1.73 per patient at baseline to 1.31 at follow-up, p < 0.05). The change in number of drugs was more pronounced in the intervention group (p < 0.046). Intervention group patients were not admitted to hospital on fewer occasions or for fewer days, and there was no significant difference between the two groups regarding utilization of primary care during follow-up. Self-rated health remained unchanged in the intervention group, whereas a drop (p < 0.02) was reported in the control group. This resulted in a significant difference in change in self-rated health between the groups (p < 0.047). The addition of a skilled pharmacist to the primary care team may contribute to reductions in numbers of drugs and maintenance of self-rated health in elderly patients with polypharmacy.

1 December 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
TFTomas Forslund
Tomas Forslund
BWBjörn Wettermark
Björn Wettermark
PWPer Wändell
Per Wändell
MEMia von Euler
Mia von Euler
JHJan Hasselström
Jan Hasselström
PHPaul Hjemdahl
Paul Hjemdahl

8 December 2001 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JPJ. Persson
J. Persson
JHJ. Hasselström
J. Hasselström
AMA. Maurset
A. Maurset
IÖI. Öye
I. Öye
JSJ.-O. Svensson
J.-O. Svensson
LGL. Gustafsson
L. Gustafsson

1 December 2014 in Journal of the American Society of Hypertension
Verified
Journal Article
Closed access
CLCharlotta Ljungman
Charlotta Ljungman
TKThomas Kahan
Thomas Kahan
LSLinus Schiöler
Linus Schiöler
PHPer Hjerpe
Per Hjerpe
JHJan Hasselström
Jan Hasselström
KMKarin Manhem
Karin Manhem